JP2021525245A5 - - Google Patents

Info

Publication number
JP2021525245A5
JP2021525245A5 JP2020565341A JP2020565341A JP2021525245A5 JP 2021525245 A5 JP2021525245 A5 JP 2021525245A5 JP 2020565341 A JP2020565341 A JP 2020565341A JP 2020565341 A JP2020565341 A JP 2020565341A JP 2021525245 A5 JP2021525245 A5 JP 2021525245A5
Authority
JP
Japan
Prior art keywords
vector
polynucleotide
promoter
use according
aav2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020565341A
Other languages
English (en)
Japanese (ja)
Other versions
JP7587423B2 (ja
JP2021525245A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/033616 external-priority patent/WO2019226832A1/en
Publication of JP2021525245A publication Critical patent/JP2021525245A/ja
Publication of JP2021525245A5 publication Critical patent/JP2021525245A5/ja
Application granted granted Critical
Publication of JP7587423B2 publication Critical patent/JP7587423B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020565341A 2018-05-22 2019-05-22 アルツハイマー病のための遺伝子治療 Active JP7587423B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862675003P 2018-05-22 2018-05-22
US62/675,003 2018-05-22
PCT/US2019/033616 WO2019226832A1 (en) 2018-05-22 2019-05-22 Gene therapy for alzheimer's disease

Publications (3)

Publication Number Publication Date
JP2021525245A JP2021525245A (ja) 2021-09-24
JP2021525245A5 true JP2021525245A5 (enExample) 2022-05-26
JP7587423B2 JP7587423B2 (ja) 2024-11-20

Family

ID=68617210

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020565341A Active JP7587423B2 (ja) 2018-05-22 2019-05-22 アルツハイマー病のための遺伝子治療

Country Status (8)

Country Link
US (1) US12497608B2 (enExample)
EP (1) EP3796980A4 (enExample)
JP (1) JP7587423B2 (enExample)
CN (1) CN112739419A (enExample)
AU (1) AU2019272848A1 (enExample)
CA (1) CA3100946A1 (enExample)
IL (1) IL278813A (enExample)
WO (1) WO2019226832A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3100946A1 (en) 2018-05-22 2019-11-28 The Brigham And Women's Hospital, Inc. Gene therapy for alzheimer's disease
JP7686573B6 (ja) * 2019-05-24 2025-07-04 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド アルツハイマー病のための遺伝子治療
BR112022010373A2 (pt) * 2019-11-29 2022-08-16 Paros Bio Inc Terapia genética para doenças neurodegenerativas
WO2022261413A1 (en) * 2021-06-10 2022-12-15 The Brigham And Women’S Hospital, Inc. Cell-based assay for identification of activators of gamma-secretase
EP4399311A4 (en) * 2021-09-10 2025-11-26 Alnylam Pharmaceuticals Inc APP ARNI COMPOSITIONS AND THEIR METHODS OF USE FOR TREATMENT OR PREVENTION OF DISEASES CHARACTERIZED BY ENLARGED ENDOSOMES
CN116024270B (zh) * 2021-12-27 2025-07-22 中国科学院昆明动物研究所 一种app/psen1双转基因阿尔茨海默病树鼩模型的建立方法
CN115125244A (zh) * 2022-05-14 2022-09-30 吉林大学 构建阿尔兹海默症的兔模型方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
WO1995013365A1 (en) 1993-11-09 1995-05-18 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
ATE386131T1 (de) 1994-04-13 2008-03-15 Univ Rockefeller Aav-vermittelte überbringung von dna in zellen des nervensystems
US5986054A (en) 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
JP2000506375A (ja) 1996-01-26 2000-05-30 エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用
AR020107A1 (es) * 1998-07-09 2002-04-10 Boehringer Ingelheim Pharma Metodo para identificar una sustancia capaz de reducir o eliminar la actividad de la presenilinasa, las sustancias identificables con dicho metodo, el usode estas ultimas en la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y las composiciones farmaceuticas que
CA2333467A1 (en) * 1998-07-16 2000-01-27 Incyte Pharmaceuticals, Inc. Human presenilin-associated protein
US6979537B2 (en) 2000-01-10 2005-12-27 Scios, Inc. Methods for identifying inhibitors of neuronal degeneration
US6686449B2 (en) 2000-06-30 2004-02-03 Pharmacia & Upjohn Company Mutant presenilin 1 polypeptides
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US7271313B2 (en) 2003-04-09 2007-09-18 The Brigham And Women's Hospital, Inc. Presenilin-deficient mouse model of age-dependent neurodegeneration and cognitive loss
CA2528963A1 (en) 2003-06-27 2005-01-13 Sirna Therapeutics, Inc. Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
WO2005037226A2 (en) 2003-10-17 2005-04-28 Georgia Tech Research Corporation Genetically engineered enteroendocrine cells for treating glucose-related metabolic disorders
PT1675956E (pt) 2003-10-21 2010-11-04 Merck Serono Sa Sequência mínima de adn que actua como um isolador de cromatina e sua utilização na expressão de proteína
WO2005096781A2 (en) 2004-04-06 2005-10-20 University Of Massachusetts Methods and compositions for treating gain-of-function disorders using rna interference
JP5697297B2 (ja) 2004-05-14 2015-04-08 ロゼッタ ジノミクス リミテッド マイクロnasおよびその使用
WO2005116250A2 (en) 2004-05-26 2005-12-08 Rosetta Genomics Ltd. Viral and viral associated mirnas and uses thereof
US8129334B2 (en) * 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
WO2009042727A1 (en) * 2007-09-24 2009-04-02 The Johns Hopkins University Immediate early gene arc interacts with endocytic machinery and regulates the trafficking and function of presenilin
KR20120089743A (ko) 2009-11-09 2012-08-13 제네포드 테라퓨틱스 에이비 생체 내에서 최적화된 뉴런 특이적 연속 도파 합성을 위한 신규한 바이러스 벡터 구성물
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
CN103816540B (zh) * 2012-11-16 2018-01-02 中国科学院上海生命科学研究院 降低β‑抑制蛋白1与APH‑1蛋白的结合的物质在制备防治神经退行性疾病药物中的应用
CN115120746A (zh) 2013-05-15 2022-09-30 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
HK1222673A1 (zh) * 2013-07-12 2017-07-07 The Children's Hospital Of Philadelphia Aav载体和用於抗aav(腺相关病毒)中和抗体的检测
GB201404470D0 (en) 2014-03-13 2014-04-30 Ucl Business Plc Therapeutic methods and materials
GB201413665D0 (en) * 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
WO2016118780A1 (en) 2015-01-21 2016-07-28 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
WO2016154055A1 (en) * 2015-03-20 2016-09-29 Bluebird Bio, Inc. Vector formulations
WO2016209654A1 (en) * 2015-06-22 2016-12-29 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
CN117018228A (zh) 2016-05-27 2023-11-10 创思瑞普泰克斯公司 用合成信使rna治疗原发性纤毛运动障碍
WO2018045022A1 (en) 2016-08-30 2018-03-08 University Of South Florida Adipose derived stem cell exosomes and uses thereof
EP3573627A4 (en) 2017-01-24 2020-11-25 Fred Hutchinson Cancer Research Center SYSTEMS AND METHODS FOR EXPANSION OF HEMATOPOIETIC CELLS USING HYDROGELS
US11713470B2 (en) 2017-03-20 2023-08-01 University of Pittsburgh—of the Commonwealth System of Higher Education Targeted gene therapies for pain and other neuro-related disorders
ES3039647T3 (en) 2017-05-31 2025-10-23 Arcturus Therapeutics Inc Synthesis and structure of high potency rna therapeutics
EP3808849A1 (en) 2017-08-03 2021-04-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
CA3100946A1 (en) 2018-05-22 2019-11-28 The Brigham And Women's Hospital, Inc. Gene therapy for alzheimer's disease
JP7686573B6 (ja) 2019-05-24 2025-07-04 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド アルツハイマー病のための遺伝子治療
BR112022010373A2 (pt) 2019-11-29 2022-08-16 Paros Bio Inc Terapia genética para doenças neurodegenerativas
JP2023512079A (ja) 2020-01-31 2023-03-23 パロス バイオ インコーポレイテッド ポリヌクレオチドサイレンシング及び置換を使用する神経変性障害のための遺伝子療法

Similar Documents

Publication Publication Date Title
JP2021525245A5 (enExample)
JP2020533959A5 (enExample)
US20250161485A1 (en) Aav capsid variants and uses thereof
JP2020500526A5 (enExample)
JP2022535749A5 (enExample)
JP2021505133A5 (enExample)
JP7616995B2 (ja) 神経変性疾患のための遺伝子治療
JP2022533451A5 (enExample)
EP3701030A1 (en) Gene therapies for neurodegenerative disease
JP2020519629A5 (enExample)
JP2021512649A5 (enExample)
JP2013531471A5 (enExample)
JP2023537980A5 (enExample)
JP2019537576A5 (enExample)
FI3373980T3 (fi) Menetelmiä lihasdystrofian hoitamiseksi
JP2023500793A5 (enExample)
CN112739419A (zh) 用于阿尔茨海默症的基因治疗
US12540334B2 (en) Gene therapy for Alzheimer's disease
JP2023059858A5 (enExample)
JP2024543253A5 (enExample)
JP2022545378A5 (enExample)
JP2023551254A (ja) 神経変性疾患のための遺伝子治療
JP2022552014A5 (enExample)
JP2023502474A5 (enExample)
JP2024530050A5 (enExample)